April 17th 2025
The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs.
April 9th 2025
Respective industry and government agendas could significantly reshape the US prescription drug market.
Ensuring that essential treatments reach patients safely and efficiently is an increasing imperative in today's pharma landscape.
April 8th 2025
How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including resource allocation, pricing, and market access.
March 20th 2025
The session provides an overview of the uninsured population, and also tackles challenges faced by patients when it comes to accessing PAPs.
FDA Approves Merck's Keytruda With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma
Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction cancer approved by FDA after being found to lower the risk of metastasis or death.
FDA Approves New Treatment for ROS1-Positive Non-Small Cell Lung Cancer
Bristol Myers Squibb’s repotrectinib (Augtyro) approved by FDA to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer.
FDA Approves Defencath to Treat Catheter-Related Bloodstream Infections
Patients with kidney failure administered chronic hemodialysis who received DefenCath showed a statistically significant lower incidence of catheter-related bloodstream infections.
Pacira BioSciences Announces FDA Approval of Expanded Indications for Exparel
Exparel was initially approved in 2011 for single-dose infiltration into a surgical site.
FDA Grants 510(k) Marketing Clearance to Flowflex COVID-19 Antigen Home Test
The Flowflex COVID-19 Antigen Home Test is the first over-the-counter rapid antigen test for SARS-CoV-2 to gain FDA 510(k) marketing clearance by the FDA.
Access Insights 2023: A View from DC
Conference presentation explores groundbreaking topics impacting the pharma industry.
Novel Chemotherapy-Free Fruzaqla Gets FDA Approval for Metastatic Colorectal Cancer
Fruquintinib (Fruzaqla) is a significant new therapy for patients who have had limited options to treat metastatic colorectal cancer.
Access Insights 2023: The Pharmacy of the Future
Conference session discusses the drivers, practical considerations, success factors, and landscape for next-generation pharmacy innovation.
Ayala Pharmaceuticals’ AL102 Granted Orphan Drug Designation by FDA
Ayala Pharmaceuticals’ AL102 is a gamma secretase inhibitor being studied to treat patients with desmoid tumors.
RSV Designations Reached All-Time High in 2022, Data Shows
Surge acted as a precursor for the RSV-marketed drug landscape in 2023, says GlobalData.
Anti-Counterfeit Packaging Market Estimated to Reach Nearly $436 Million by 2030
Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.
Drilling Down On Distribution
Pharma Commerce converges on Nation's Capital for HDA Traceability Seminar.
FDA Releases Draft Guidance for Regulatory Considerations for Prescription Drug-Use-Related Software
The agency differentiates between software that has a notable impact on the effectiveness and safety of drug use.
Congress Is Expected to Bring PBM Transparency Legislation
PBM transparency and data reporting requirements are likely to be part of a larger healthcare bill that Congress will work on this fall.
HDA 2023 Traceability Seminar: GS1 Updates on Implementation Guides
Pharma Commerce provides a synopsis of the presentation.
FTC, Amgen Reach Settlement on Dispute Over Horizon Therapeutics Acquisition
Biopharma company now required to seek approval before attempting further buyouts.
HDA 2023 Traceability Seminar: DSCSA Roundtable Discussions
Attendees meet to discuss operational issues related to traceability implementation.
HDA 2023 Traceability Seminar: DSCSA Areas of Improvement
Session offers information on industry readiness, plus an overview of a phase implementation recommendation.
HDA 2023 Traceability Seminar: A Synopsis of FDA’s Enforcement Policies and Guidance Updates
Pharma Commerce provides a summary of conference breakout session.
Report: FTC Temporarily Suspends Challenge to $27.8B Amgen-Horizon Merger
Delay to allow agency to consider other ways of solving the issue, filing says.
Illinois Governor Signs Legislation Targeting PBM Retaliation
Illinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.
LSPedia Receives Inc. 5000 Ranking Honor
In the midst of providing DSCSA support, the SaaS provider is awarded for being a fast-growing, private US company.
Clinigen Divests Global Rights to Four Cancer Support Medications
Company will focus on its managed access services.
Boyds Rolls Out Regulatory Operations Service
Offering provides assistance through the post-approval lifecycle of drugs.
The Voyage to Beantown
Pharma Commerce team attends DIA's Annual Meeting for the first time.
Citing Suspected Vaccine Patent Infringement, GSK Files Lawsuit Against Pfizer
Company is seeking monetary damages from the alleged violation.
Breaking the Pharma Industry’s Bundled Pricing Arrangements
How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.
FTC Files Lawsuit to Prevent IQVIA Propel Media Purchase
Agency claims union would threaten a monopoly on programmatic advertising space.
Addressing Revenue Leakage
Micah Litow, Kalderos’ president and COO, discusses the importance of identifying and resolving noncompliant discount requests, along with addressing the gross-to-net gap for drug manufacturers.
DSCSA: A Fast-Approaching Deadline
The legislation’s deadline for compliance is knocking on the door. Pharma Commerce offers a synopsis of how the Drug Supply Chain Security Act has progressed over the past decade.